Home › Funds › Patient Square Capital LP › XENE

Patient Square Capital LP position in XENE

XENON PHARMACEUTICALS INC · Health Care

Patient Square Capital LP reported holding 220,000 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$13.3M, representing 2.06% of its reported portfolio and ranking #12 among its reported holdings. Patient Square Capital LP has disclosed XENE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)220.00K sh
Reported value held$13.28M
Portfolio Weight2.06%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Patient Square Capital LP's XENE position evolved

Patient Square Capital LP first disclosed a stake in XENE in Q4 2025 at 136,500 shares (US$6.1M). The position peaked in Q2 2026 at 220,000 shares, worth US$13.3M. Across 3 filings, Patient Square Capital LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 220,000 shares valued at US$13.3M — a reduction of -7,000 shares quarter over quarter.. Notable position changes include a 66% increase in Q1 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 136.50K $6.12M New
Q1 2026 227.00K $13.20M Add
Q2 2026 220.00K $13.28M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has Patient Square Capital LP held XENE?

Patient Square Capital LP has disclosed XENE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Patient Square Capital LP's current position in XENE?

As of Q2 2026, Patient Square Capital LP holds 220.00K shares of XENE (XENON PHARMACEUTICALS INC), valued at $13.28M, representing 2.06% of its reported portfolio and ranking #12.

Has Patient Square Capital LP been buying or selling XENE?

In the latest 13F filing (Q2 2026), Patient Square Capital LP reduced its position in XENE. The position peaked in Q2 2026 at 220.00K shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.